Israeli Medtech Firm IceCure Gains FDA Approval for Post-Market Breast Cancer Study
IceCure Medical's ProSense cryoablation, a minimally invasive breast cancer treatment, is now under FDA review in a post-market study called "ChoICE.".




















IceCure Medical's ProSense cryoablation, a minimally invasive breast cancer treatment, is now under FDA review in a post-market study called "ChoICE.".
Israeli MedTech Firm IceCure gains Swiss approval for revolutionary cryoablation cancer therapy, expanding global reach with innovative treatment options.